Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Total Current Liabilities (2019 - 2025)

IDEAYA Biosciences' Total Current Liabilities history spans 7 years, with the latest figure at $58.8 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 27.66% year-over-year to $58.8 million; the TTM value through Dec 2025 reached $58.8 million, up 27.66%, while the annual FY2025 figure was $58.8 million, 27.66% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $58.8 million at IDEAYA Biosciences, down from $64.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $64.5 million in Q3 2025 and bottomed at $24.9 million in Q3 2023.
  • The 5-year median for Total Current Liabilities is $39.6 million (2021), against an average of $41.2 million.
  • The largest annual shift saw Total Current Liabilities surged 391.82% in 2021 before it plummeted 56.38% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $45.2 million in 2021, then fell by 29.76% to $31.7 million in 2022, then dropped by 14.56% to $27.1 million in 2023, then soared by 70.0% to $46.1 million in 2024, then rose by 27.66% to $58.8 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Total Current Liabilities are $58.8 million (Q4 2025), $64.5 million (Q3 2025), and $55.3 million (Q2 2025).